Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics
The gastrointestinal tract (GIT) is an important and complex system by which humans to digest food and absorb nutrients. The GIT is vulnerable to diseases, which may led to discomfort or even death in humans. Therapeutics for GIT disease treatment face multiple biological barriers, which significant...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Drug Delivery |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/10717544.2024.2415580 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849687559401111552 |
|---|---|
| author | Shan Li Tianyu Wu Jingfeng Wu Wensheng Chen Dinglin Zhang |
| author_facet | Shan Li Tianyu Wu Jingfeng Wu Wensheng Chen Dinglin Zhang |
| author_sort | Shan Li |
| collection | DOAJ |
| description | The gastrointestinal tract (GIT) is an important and complex system by which humans to digest food and absorb nutrients. The GIT is vulnerable to diseases, which may led to discomfort or even death in humans. Therapeutics for GIT disease treatment face multiple biological barriers, which significantly decrease the efficacy of therapeutics. Recognizing the biological barriers and pathophysiological characteristics of GIT may be helpful to design innovative therapeutics. Nanotherapeutics, which have special targeting and controlled therapeutic release profiles, have been widely used for the treatment of GIT diseases. Herein, we provide a comprehensive review of the biological barrier and pathophysiological characteristics of GIT, which may aid in the design of promising nanotherapeutics for GIT disease treatment. Furthermore, several typical diseases of the upper and lower digestive tracts, such as Helicobacter pylori infection and inflammatory bowel disease, were selected to investigate the application of nanotherapeutics for GIT disease treatment. |
| format | Article |
| id | doaj-art-e5c42867e71d4e99861577cdacebdbb5 |
| institution | DOAJ |
| issn | 1071-7544 1521-0464 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Drug Delivery |
| spelling | doaj-art-e5c42867e71d4e99861577cdacebdbb52025-08-20T03:22:18ZengTaylor & Francis GroupDrug Delivery1071-75441521-04642024-12-0131110.1080/10717544.2024.2415580Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeuticsShan Li0Tianyu Wu1Jingfeng Wu2Wensheng Chen3Dinglin Zhang4Department of Chemistry, College of Basic Medicine, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Gastroenterology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Gastroenterology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Gastroenterology, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, ChinaDepartment of Chemistry, College of Basic Medicine, Army Medical University (Third Military Medical University), Chongqing, ChinaThe gastrointestinal tract (GIT) is an important and complex system by which humans to digest food and absorb nutrients. The GIT is vulnerable to diseases, which may led to discomfort or even death in humans. Therapeutics for GIT disease treatment face multiple biological barriers, which significantly decrease the efficacy of therapeutics. Recognizing the biological barriers and pathophysiological characteristics of GIT may be helpful to design innovative therapeutics. Nanotherapeutics, which have special targeting and controlled therapeutic release profiles, have been widely used for the treatment of GIT diseases. Herein, we provide a comprehensive review of the biological barrier and pathophysiological characteristics of GIT, which may aid in the design of promising nanotherapeutics for GIT disease treatment. Furthermore, several typical diseases of the upper and lower digestive tracts, such as Helicobacter pylori infection and inflammatory bowel disease, were selected to investigate the application of nanotherapeutics for GIT disease treatment.https://www.tandfonline.com/doi/10.1080/10717544.2024.2415580Nanotherapeuticsgastrointestinal tractinflammatory bowel diseaseHelicobacter pylori infection |
| spellingShingle | Shan Li Tianyu Wu Jingfeng Wu Wensheng Chen Dinglin Zhang Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics Drug Delivery Nanotherapeutics gastrointestinal tract inflammatory bowel disease Helicobacter pylori infection |
| title | Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics |
| title_full | Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics |
| title_fullStr | Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics |
| title_full_unstemmed | Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics |
| title_short | Recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics |
| title_sort | recognizing the biological barriers and pathophysiological characteristics of the gastrointestinal tract for the design and application of nanotherapeutics |
| topic | Nanotherapeutics gastrointestinal tract inflammatory bowel disease Helicobacter pylori infection |
| url | https://www.tandfonline.com/doi/10.1080/10717544.2024.2415580 |
| work_keys_str_mv | AT shanli recognizingthebiologicalbarriersandpathophysiologicalcharacteristicsofthegastrointestinaltractforthedesignandapplicationofnanotherapeutics AT tianyuwu recognizingthebiologicalbarriersandpathophysiologicalcharacteristicsofthegastrointestinaltractforthedesignandapplicationofnanotherapeutics AT jingfengwu recognizingthebiologicalbarriersandpathophysiologicalcharacteristicsofthegastrointestinaltractforthedesignandapplicationofnanotherapeutics AT wenshengchen recognizingthebiologicalbarriersandpathophysiologicalcharacteristicsofthegastrointestinaltractforthedesignandapplicationofnanotherapeutics AT dinglinzhang recognizingthebiologicalbarriersandpathophysiologicalcharacteristicsofthegastrointestinaltractforthedesignandapplicationofnanotherapeutics |